Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918162 · ClinicalTrials.gov registry record · Phase 2
Perioperative Chemo and Pembrolizumab in Gastric Cancer
A Phase 2 study, sponsored by Gulam Manji.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02918162 is a Phase 2 study that has completed, run by Gulam Manji. The registered enrollment target is 49 participants.
The verdict
NCT02918162, a Phase 2 study, has completed, sponsored by Gulam Manji.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma. The purpose of this study is to determine and evaluate the efficacy of combination therapy with immune checkpoint blockade and chemotherapy used in the perioperative period in eradicating micrometastatic disease; and to compare paired tissue and serum samples (pre-treatment and post-treatment) from individually treated patients to explore the immune effects of combination therapy and predictors of response.
Interventions
- DRUG Pembrolizumab
- DRUG Standard of care chemotherapy regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-11-25 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918162
The ClinicalTrials.gov registry entry for NCT02918162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gulam Manji, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02918162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918162 about?
NCT02918162 is a clinical study titled "Perioperative Chemo and Pembrolizumab in Gastric Cancer". This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma. The purpose of this study is to determine and evaluate the efficacy of combination therapy with immune checkpoint blockade and chemother...
What is the current status of trial NCT02918162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2017-11-25. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT02918162?
The interventions under investigation include: Pembrolizumab (DRUG), Standard of care chemotherapy regimen (DRUG).
Who is sponsoring clinical trial NCT02918162?
This trial is sponsored by Gulam Manji, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.